GPR52 Comp-43

Key Product Details

Product Description

GPR52 Comp-43 is a GPR52 receptor antagonist (IC₅₀ = 0.63 μM). The use of GPR52 Comp-43 in animal models of Huntington's Disease leads to degradation and reduction of soluble and aggregated mutant huntingtin protein in the striatum. It also reduces neuronal loss, promotes neuronal survival and improves motor functions in vivo. GPR52 Comp-43 is active in vitro and brain penetrant.

Product Specifications for GPR52 Comp-43

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for GPR52 Comp-43

The following data is based on the product molecular weight 242.34.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	4.13 mL	20.63 mL	41.26 mL
5 mM	0.83 mL	4.13 mL	8.25 mL
10 mM	0.41 mL	2.06 mL	4.13 mL
50 mM	0.08 mL	0.41 mL	0.83 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Komatsu Discovery of the first druggable GPR52 antagonist to treat Huntington's disease. J.Med.Chem. 2021 PMID: 33443413
• Wang GPR52 antagonist reduces huntingtin levels and ameliorates Huntington's disease-related phenotypes. J.Med.Chem. 2021 PMID: 33185430

Product Documents for GPR52 Comp-43